Log in
Enquire now
‌

US Patent 11230534 KDM1A inhibitors for the treatment of disease

Patent 11230534 was granted and assigned to Imago BioSciences Inc on January, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Imago BioSciences Inc
Imago BioSciences Inc
Current Assignee
Imago BioSciences Inc
Imago BioSciences Inc
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11230534
Patent Inventor Names
Hugh Y. Rienhoff, Jr.0
Michael Clare0
Amy E. Tapper0
Cassandra Celatka0
John M. McCall0
Date of Patent
January 25, 2022
Patent Application Number
16672083
Date Filed
November 1, 2019
Patent Citations Received
‌
US Patent 11578059 KDM1A inhibitors for the treatment of disease
‌
US Patent 11932629 KDM1A inhibitors for the treatment of disease
0
‌
US Patent 11655226 KDM1A inhibitors for the treatment of disease
0
Patent Primary Examiner
‌
Samantha L Shterengarts
Patent abstract

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11230534 KDM1A inhibitors for the treatment of disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.